ProBioGen Plans Biologics ExpansionBy
ProBioGen AG, a contract biologics manufacturer based in Berlin, plans to invest EUR 20 million ($26 million) and to double its workforce.
ProBioGen develops biotechnological processes for the production of biopharmaceutical drug substances. Its service spectrum ranges from cell line and process development up to GMP contract manufacturing. With the planned investment, the company plans to add two additional disposable 1000-L bioreactors, and within the next two years, it will double its staff. The company currently has 75 employees. .